()2\/ent®



13 May 2020

ASX Release

ASX Waiver for General Meeting of Members

WAIVER PURSUANT TO ASX LISTING RULE 7.3.9

Oventus Medical Limited (Company) is pleased to advise that the Australian Securities Exchange (ASX) has today provided the Company with a waiver under ASX Listing Rule 7.3.9 in respect of the voting exclusion for Resolution 6 in the Notice of General Meeting dispatched to Shareholders today for its General Meeting to be held on 12 June 2020 (Notice of Meeting).

As advised in the Notice of General Meeting, the Company had sought a waiver from the ASX to the extent necessary to permit those who participate in the Share Purchase Plan (SPP) announced on 5 May 2020 to vote on resolution 6 of the meeting, namely, the resolution to approve the issue of the options under the SPP (SPP Options).

Pursuant to this waiver, all Shareholders who participate in the SPP (excluding the underwriters, any sub-underwriters or any investor who may receive securities under any SPP Shortfall) are entitled to vote on resolution 6 of the meeting to approve the issue of the SPP Options. Specifically, the ASX has provided the following formal decision:

"Waiver Decision

- 1. Based solely on the information provided, ASX Limited ('ASX') grants Oventus Medical Limited (the 'Company') a waiver from listing rule 7.3.9 to the extent necessary to permit the Company to include a resolution in the Company's notice of meeting ('Notice') to approve the issue of up to 4,166,667 free attaching options to acquire fully paid ordinary shares at an exercise price of \$0.36 and expiry date of 30 June 2021 or the day that is 12 months after the date of issue, to eligible shareholders under the Company's Share Purchase Plan ('SPP'), not to include a voting resolution that that excludes the votes of persons who may participate in the SPP, on the following conditions:
 - 1.1. that the SPP is not underwritten, or if it is underwritten, the Company excludes any votes cast in favour of that resolution by any proposed underwriter or sub-underwriter of the SPP: and
 - 1.2. that the Company excludes any votes cast in favour of that resolution by any investor who may receive securities under any SPP shortfall.
- 2. ASX has considered Listing Rule 7.3.9 only and makes no statement as to the Company's compliance with other listing rules

Basis for Waiver Decision Listing Rule 7.3.9

3. Standard waiver in accordance with Guidance Note 17."

O₂Vent®



We look forward to your participation at the General Meeting on 12 June 2020, at 11 a.m. (Brisbane time).

Authorised and approved by the Board.

For and on behalf of Oventus Medical Limited.

Stephen Denaro Company Secretary Oventus Medical Limited